Status:
COMPLETED
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. This study also tests how semaglutide 50 mg works on appetite, control of ...
Eligibility Criteria
Inclusion
- Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent
- Body mass index between 30.0 and 45.0 kilogram per meter square (kg/m\^2) (both inclusive)
Exclusion
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method
- Any disorder which in the investigator's opinion might jeopardise participant safety or compliance with the protocol
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions
Key Trial Info
Start Date :
February 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05236517
Start Date
February 8 2022
End Date
November 7 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parexel International GmbH
Berlin, Germany, 14050